Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Arch Therapeutics's enterprise value is $0.00 Mil.
Arch Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was $-8.68 Mil. Therefore, Arch Therapeutics's EV-to-EBITDA for today is 0.00.
The historical rank and industry rank for Arch Therapeutics's EV-to-EBITDA or its related term are showing as below:
ARTHQ's EV-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 11.92 * Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Arch Therapeutics's PE Ratio (TTM) for today is calculated as:
Arch Therapeutics's share price for today is $0.0001.
Arch Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.864.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Arch Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARTHQ vs GRTSQ, MTEM, PXMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Arch Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arch Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arch Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Arch Therapeutics's EV-to-EBITDA falls into.
Arch Therapeutics's current Enterprise Value is $0.00 Mil.
Arch Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.68 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arch Therapeutics (ARTHQ) has a EV-to-EBITDA of 0.00 as of Aug. 04, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Arch Therapeutics.
Is Arch Therapeutics' EV-to-EBITDA too high?
Arch Therapeutics' current EV-to-EBITDA is 0.00. Overall, Arch Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Arch Therapeutics' EV-to-EBITDA compare to GRTSQ and MTEM?
Arch Therapeutics' EV-to-EBITDA of 0.00 can be compared against companies in the Biotechnology industry. The industry median EV-to-EBITDA is 11.92. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 11.92, based on 415 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Arch Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 11.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arch Therapeutics's current EV-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arch Therapeutics stock overvalued right now?
Arch Therapeutics (ARTHQ) has a current EV-to-EBITDA of 0.00. The current EV-to-EBITDA is 0.00. Arch Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Arch Therapeutics (ARTHQ), the current EV-to-EBITDA is 0.00 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Arch Therapeutics Inc is a development-stage biotechnology company. It focuses on developing products that manage surgery and interventional care faster and safer by using a novel approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The company's primary product candidate, collectively known as the AC5 Devices (AC5), is designed to achieve hemostasis in surgical procedures. The company operates its business operations in the United States.
12GF Score
Get the complete analysis for ARTHQ
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARTHQ has been successfully added to your 
